562 related articles for article (PubMed ID: 21168715)
1. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
[TBL] [Abstract][Full Text] [Related]
4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
5. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
[TBL] [Abstract][Full Text] [Related]
6. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
9. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
[TBL] [Abstract][Full Text] [Related]
10. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
[TBL] [Abstract][Full Text] [Related]
11. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
[TBL] [Abstract][Full Text] [Related]
12. [Early conversion from calcineurin inhibitor to sirolimusto after renal transplantation:a prospective, open-label and non-randomized control study].
Huang H; Xie W; Wu J; Xu Y; Yu X; Ren P; Chen J
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(42):3293-7. PubMed ID: 25622626
[TBL] [Abstract][Full Text] [Related]
13. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
14. Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor.
Eisenberger U; Sollinger D; Stickel F; Burckhardt B; Frey FJ
Clin Transplant; 2009; 23(4):499-504. PubMed ID: 19486346
[TBL] [Abstract][Full Text] [Related]
15. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM
Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413
[TBL] [Abstract][Full Text] [Related]
16. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
17. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
Guba M; Pratschke J; Hugo C; Krämer BK; Nohr-Westphal C; Brockmann J; Andrassy J; Reinke P; Pressmar K; Hakenberg O; Fischereder M; Pascher A; Illner WD; Banas B; Jauch KW;
Transplantation; 2010 Jul; 90(2):175-83. PubMed ID: 20463641
[TBL] [Abstract][Full Text] [Related]
18. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
19. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients.
Tsai MK; Lee CY; Hu RH; Lee PH
J Formos Med Assoc; 2007 May; 106(5):372-9. PubMed ID: 17561472
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure.
Groetzner J; Meiser B; Landwehr P; Buehse L; Mueller M; Kaczmarek I; Vogeser M; Daebritz S; Ueberfuhr P; Reichart B
Transplantation; 2004 Feb; 77(4):568-74. PubMed ID: 15084937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
